Clinical Trial

A Phase 2 Study of HB0017 in Psoriasis Patients

Study acronym: HB0017
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque psoriasis in subjects
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-09.
Status change: Not Yet Recruiting → Recruiting 2025-09-09
Trial Details
NCT Number NCT06592274
Lead Sponsor Huabo Biopharm Co., Ltd.
Conditions Psoriasis (PsO)
Enrollment 200 participants
Start Date 2024-09-30
Primary Completion 2025-04-30 (estimated)
Study Completion 2026-01-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-15